Evidence map›Paper›PMID 41419771›Full record

ArticleNature communications2025

IDH2 lactylation promotes angiogenesis in murine diabetic myocardial infarction via blocking Cav1-eNOS interaction.

Guangyao Zang, Siting Xu, Zhen Sun, Lili Zhang, Yongjiang Qian, Haipeng Yao, Lihua Li, Zhongqun Wang

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Lactylation in cardiac repair: Nexus and therapeutic opportunity.Journal of molecular and cellular cardiology plus · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guangyao ZangDepartment of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.ORCID http://orcid.org/0000-0001-9381-3593
Siting XuDepartment of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Zhen SunDepartment of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Lili ZhangDepartment of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Yongjiang QianDepartment of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Haipeng YaoDepartment of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Lihua LiDepartment of Pathology, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Zhongqun WangDepartment of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, China. wangtsmc@126.com.ORCID http://orcid.org/0000-0003-3590-9313

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compensatory angiogenesis is critical for preserving left ventricular function after myocardial infarction; however, this process is severely impaired in diabetes, exacerbating adverse outcomes in diabetic myocardial infarction (DMI). This study employed liquid chromatography-tandem mass spectrometry to identify lactylated proteins in the infarct border zone of DMI male mouse hearts. Our findings revealed that IDH2 is lactylated at lysine 272, enhancing its binding to Cav1 while inhibiting the Cav1-eNOS interaction. This modification promotes eNOS activity and facilitates the proliferation, migration, and angiogenesis of cardiac microvascular endothelial cells under high glucose and hypoxic conditions. In endothelial cell-specific IDH2-K272R knock-in male mice, the loss of K272 lactylation impairs cardiac function and exacerbates pathological remodeling due to disrupted angiogenesis. Additionally, ACAT1 and HDAC1 act as lactyltransferase and delactylase, respectively, utilizing intracellular lactate transported via MCT1 as a substrate for IDH2 lactylation. Furthermore, pharmacologic enhancement of IDH2 lactylation, as demonstrated by empagliflozin mitigating post-DMI injury, supports its potential as a therapeutic target for DMI.

Indexed as

Isocitrate DehydrogenaseMyocardial InfarctionNeovascularization, PathologicNeovascularization, PhysiologicNitric Oxide Synthase Type IIIAngiogenesisAnimalsCell MovementCell ProliferationDiabetes Mellitus, ExperimentalEndothelial CellsHistone Deacetylase 1HumansMaleMiceMice, Inbred C57BLHdac1 protein, mouseHistone Deacetylase 1Isocitrate Dehydrogenaseisocitrate dehydrogenase 2, mouseNitric Oxide Synthase Type IIINos3 protein, mouse

Identifiers

PMID41419771
PMCPMC12855196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.